ALSO NOTED: Impotence drug labels revised; Roche, GE to collaborate; Esprit buys rights to Sanctura; and much more...

> The FDA has approved revised labels for Levitra, Cialis and Viagra, warning users of a slight increase in the risk of sudden blindness. Story

> Roche and GE Healthcare will collaborate on upcoming tests of Roche's experimental Alzheimer's treatment. Report

> Esprit Pharma has acquired the US rights to Sanctura, a newly approved drug for overactive bladder. Report

> Abbott has struck a deal with the Brazilian government for its AIDS drug Kaletra. Story

> Canada's HepaLife Technologies has arranged up to $15 million in equity financing. Release

> Novartis has filed new applications to expand the use of Femara. Report

And Finally... The opening shot in what is widely expected to be a multibillion-dollar legal war over Merck's liability for Vioxx will get started this week in a small South Texas courtroom. Article

Suggested Articles

The public financing will enable Monopar to start a phase 3 trial of a prophylactic treatment for a side effect of chemoradiotherapy. 

The dispute centers on whether Asa Abeliovich used Alector’s confidential information in connection with his work for Prevail Therapeutics.

GSK poaches Merck KGaA's Martinez-Davis to helm pharma stateside; Bulto named Novartis U.S. pharma head; Allergan's Saunders set for huge parachute.